FDA approves CF treatment Full Text
Drug Topics,

Cystic fibrosis (CF), a disorder of the lungs and other organs that affects about 30,000 people in the United States, is caused by mutations in the gene encoding the CFTR protein. On January 31, FDA approved ivacaftor (Kalydeco) to treat CF in patients 6 years of age and older who have a G551D mutation in the CFTR gene. Approximately 4% of CF patients, roughly 1,200 people, have this mutation.

Please login or register to follow this author.
► Click here to access Full Text, PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Pharma News

See All >> Messages include industry-sponsored communications and special communications from MDLinx


Most Popular Pharma News Articles

1 Duke team brings life-saving function to ketchup packets Duke University Health & Medicine News, July 3, 2014

2 Teva announces launch of first Generic Celebrex Capsules in the United States Full Text Teva Pharmaceutical Industries, December 12, 2014    Free full text

3 FDA issues warning letter to Cadila Pharmaceuticals for CGMP deviations Full Text BioPharm International, December 3, 2014    Free full text

4 Twenty-four-year demographic trends of a Brazilian long-term care institution for the aged Journal of the American Medical Directors Association, December 24, 2014    Clinical Article

5 Acetaminophen prescription combination drug products with more than 325 mg: FDA statement – recommendation to discontinue prescribing and dispensing Full Text Purdue Pharma, November 21, 2014    Free full text

6 Bristol-Myers Squibb receives accelerated approval of opdivo (nivolumab) from the U.S. Food and Drug Administration Full Text Bristol Myers-Squibb, December 24, 2014    Free full text

7 Merck statement regarding CUBICIN patent litigation Full Text Merck, December 10, 2014    Free full text

8 Recent and future drug approvals for important disease states First Report Managed Care, December 4, 2014

9 FDA Approves Tevas GRANIX (tbo-filgrastim) injection for self-administration Full Text Teva Pharmaceutical Industries, December 24, 2014    Free full text

10 Daiichi Sankyo and Ambit announce results of tender offer Full Text Daiichi Sankyo, December 24, 2014    Free full text

11 ImmunoGen reports roche has provided an update on the MARIANNE trial Full Text ImmunoGen, Inc., December 24, 2014    Free full text

12 Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. initiate two phase 3 clinical trials on Charleston's Lead Product, CL-108 Full Text Daiichi Sankyo, December 24, 2014    Free full text

13 First successful vaccination against “mad cow”-like wasting disease in deer NYU Langone Medical Center, December 24, 2014

14 FDA approves weight-management drug Saxenda Full Text FDA Press Announcements, December 24, 2014    Free full text

15 Pfizer reports top-line results from a phase 3 study evaluating pregabalin controlled-release formulation as a treatment for patients with postherpetic neuralgia Full Text Pfizer, December 19, 2014    Free full text

16 Blocking excessive division of cell powerhouses reduces liver cell death Georgia Regents University & Health System News, December 24, 2014

17 Baxter celebrates 25 years of building a sustainable healthcare future for patients, employees and the community in China Full Text Baxter, December 24, 2014    Free full text

18 Daiichi Sankyo receives approval for additional indications of LIXIANA (edoxaban) in Japan Full Text Daiichi Sankyo, December 24, 2014    Free full text

19 Announcement under Irish Takeover Rules Relevant Securities in Issue - December 23, 2014 Covidien, December 24, 2014

20 ARIAD and Otsuka announce co-development and commercialization agreement for iclusig to treat leukemias in Japan and nine other asian countries Full Text ARIAD Pharmaceuticals, December 24, 2014    Free full text

Indexed Journals in Pharma News: U.S.Pharmacist, FDA Drug Alerts, Pharmiwebmore

Make smarter career moves with less time.

Sign up for our free job placement service today and have a dedicated career consultant help locate the right physician job for you!
Click Here for more information.

Get Started Now!

Free-of-charge, no obligation.

Terms and Conditions For M3 Career Consult

By registering with the M3 Career Consult service you authorize M3 USA Corporation to represent you in your job search. The following is a summary of the terms of our service and our mutual obligations to help you find a job:

  • You designate M3 to act as your agent and represent you in your job search;
  • You will not pay us for this service
  • You will advise us of any companies or positions to which you apply or have applied;
  • You will advise us if you believe you are not capable of performing a position for which we submit you, or for which you interview;
  • You will keep all information we provide you about companies or positions strictly confidential;
  • You will promptly provide us with information we request of you;
  • You will make yourself reasonably available for phone, video and in-person conversations and interviews;
  • You will be truthful in all of your communications with us; and
  • You will advise us if anything above changes.

The Top Read Articles of 2014 are Now Available

Scouring thousands of peer-reviewed journals and popular press, Our Editors just released the Top Read Articles of the Year. See the Top Read List